A phase 2 study of BMS-754807 combined With letrozole or BMS-754807 alone in hormone receptor-positive breast cancer subjects with acquired resistance to non-steroidal aromatase inhibitors

Trial Profile

A phase 2 study of BMS-754807 combined With letrozole or BMS-754807 alone in hormone receptor-positive breast cancer subjects with acquired resistance to non-steroidal aromatase inhibitors

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs BMS 754807 (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 30 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top